Experimental technology of chemoperfusion treatment for abdominal carcinomatosis in ovarian cancer
PDF (Русский)

Keywords

peritoneal carcinomatosis
ovarian cancer
normothermic and hyperthermic intraperitoneal chemoperfusion

How to Cite

, , , , , , , , , , , & . (2014). Experimental technology of chemoperfusion treatment for abdominal carcinomatosis in ovarian cancer. Voprosy Onkologii, 69(5), 71–79. https://doi.org/10.37469/0507-3758-2014-60-1-71-79

Abstract

An experimental technology of normothermic intraperitoneal chemoperfusion and hyperthermic intraperitoneal chemoperfusion with cisplatin and dioxadet has been elaborated to treat abdominal carcinomatosis in ovarian cancer. Antitumor effects of the treatment were evaluated for the duration of animal life. Normothermic intraperitoneal chemoperfusion and hyperthermic intraperitoneal chemoperfusion with cisplatin and dioxadet in comparison with the standard intraperitoneal administration significantly increased the median life expectancy by 75-92%. Hyperthermic intraperitoneal chemoperfusion with dioxadet demonstrated potentiation of antitumor effect of hyperthermia and dioxadet. Experimental technology is recommended for testing new drugs and methods of chemoperfusion for malignant tumors affecting the peritoneum.
https://doi.org/10.37469/0507-3758-2014-60-1-71-79
PDF (Русский)

References

Беляев А.М., Багненко С.Ф., Рухляда Н.В. Внутрибрюшинная химиотерапия злокачественных опухолей брюшной полости. - СПб.: ЭЛБИ - СПб. - 2007. -254 с.

Беляева О.А., Беспалов В.Г., Сенчик К.Ю. и др. Химиоперфузионное лечение злокачественных опухолей // Медлайн экспресс. - 2011. - № 2-3. - С. 58-65.

Беспалов В.Г., Беляева О.А., Панченко А.В. и др. Противоопухолевое действие диоксадэта в сравнении с цисплатином на модели асцитной опухоли яичника у крыс // Вопр. онкол. - 2011. - Т. 57, № 6. - С. 770-774.

Высоцкий М.М. Новое в морфогенезе и эпидемиологии рака яичников // Опухоли женской репродуктивной системы. - 2012. - № 2. - С. 39-43.

Злокачественные новообразования в России в 2011 году (заболеваемость и смертность) / Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. -М.: ФГБУ “МНИОИ им. П.А. Герцена” Минздрава России. - 2013. - 289 с.

Каирбаева М.Ж. Анализ результатов комбинированного лечения больных распространенным раком яичников // Сиб. онкол. журнал. - 2009. - № 4. - С. 71-74.

Погосянц Е.Е., Пригожина Е.Л., Еголина Н.А. Перевиваемая асцитная опухоль яичника крысы (штамм ОЯ) // Вопр. онкол. - 1962 - Т. 8, № 11. - С. 29-36.

Урманчеева А.Ф. Кутушева Г.Ф., Ульрих Е.А. Опухоли яичника (клиника, диагностика и лечение). - СПб.: Изд-во Н-Л, - 2012. - 68 с.

Chua T.C., Robertson G., Liauw W. et al. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results // J. Cancer Res. Clin. Oncol. - 2009. - Vol. 135. - P. 1637-1645.

de Bree E., Helm C.W. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data // Expert Rev. Anticancer Ther. - 2012. - Vol. 12. - P. 895-911.

De Souza R., Zahedi P., Moriyama E.H. et al. Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer // Mol. Cancer Ther. - 2010. - Vol. 9. - P. 1820-1830.

Facy O., Radais F., Ladoire S. et al. Comparison of hyperthermia and adrenaline to enhance the intratumoral accumulation of cisplatin in a murine model of peritoneal carcinomatosis // J Exp Clin. Cancer Res. - 2011. -Vol. 30:4. - http://www.jeccr.com/content/30/V4

Ferlay J., Shin H.R., Bray F. et al. Cancer incidence and mortality worldwide // IARC Cancer Base № 10. -France, Lyon: International Agency for Research on Cancer, 2010. - http://globocan.iarc.fr.

Goff B.A., Mandel L.S., Drescher C.W. et al. Development of an ovarian cancer symptom index: possibilities for earlier detection // Cancer. - 2007. - Vol. 109. - P. 221-227.

Helm C.W., Richard S.D., Pan J. et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry // Int. J. Gynecol. Cancer. - 2010. - Vol. 20. - P. 61-69.

Kemp Z., Ledermann J. Update on first-line treatment of advanced ovarian carcinoma // Int. J. Womens Health. - 2013. - Vol. 5. - P. 45-51.

Kerbel R.S. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived - but they can be improved // Cancer Biol. Ther. - 2003. - Vol. 2 (4 Suppl. 1). - P. 134-139.

Mackay H.J., Provencheur D., Heywood M. et al. Phase II/III study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: ncic ctg ov.21 // Curr. Oncol. - 2011. - Vol. 18. - P. 84-90.

Muenyi C.S., States V.A., Masters J.H. et al. Sodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC) // J Ovarian Res. - 2011. - Vol. 4:9. - http://www.ovarianresearch. com/content/4/1/9.

Wu Y.J., Muldoon L.L., Dickey D.T et al. Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models // Neoplasia. - 2009. - Vol. 11. - P. 187-195.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2014